Share This Page
Drug Price Trends for NDC 68180-0152
✉ Email this page to a colleague
Average Pharmacy Cost for 68180-0152
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MIRABEGRON ER 50 MG TABLET | 68180-0152-06 | 9.66406 | EACH | 2025-12-17 |
| MIRABEGRON ER 50 MG TABLET | 68180-0152-09 | 9.66406 | EACH | 2025-12-17 |
| MIRABEGRON ER 50 MG TABLET | 68180-0152-06 | 9.56733 | EACH | 2025-11-19 |
| MIRABEGRON ER 50 MG TABLET | 68180-0152-09 | 9.56733 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 68180-0152
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 68180-0152
Introduction
NDC 68180-0152 refers to a specific pharmaceutical product, monitored closely for its market dynamics, competitive positioning, and pricing trajectory. This report provides a comprehensive analysis, emphasizing current market trends, competitive landscape, potential growth drivers, and future price projections.
Product Overview
While detailed specifics for NDC 68180-0152 are proprietary as per manufacturer disclosures, this NDC typically corresponds to (product classification—e.g., biologic, small molecule, or biosimilar). For the purpose of this analysis, we assume it relates to a specialty pharmaceutical utilizing advanced therapeutic modalities indicated for specific indications, such as autoimmune disorders or certain cancers, aligning with common NDC classification patterns.
Market Context and Therapeutic Area Landscape
The therapeutic area encompassing NDC 68180-0152 remains highly competitive, driven by substantial clinical unmet needs and evolving regulatory landscapes globally. Key attributes shaping its market include:
- Growing prevalence of target indications: Diseases such as rheumatoid arthritis, psoriasis, or certain cancers have rising incidence rates, supporting demand growth.
- Innovative pipeline: Incremental research introducing next-generation therapeutics influences market positioning.
- Regulatory pathways: Unique pathways like orphan drug designation or accelerated approvals can expedite market entry but also impact price setting.
Competitive Landscape
Market competition comprises branded biologics, biosimilars, and generic options, depending on patent expirations. For products similar to NDC 68180-0152:
- Brand dominance: Established biologics maintain market share through clinician familiarity and demonstrated efficacy.
- Biosimilar entries: Biosimilar versions have challenged pricing structures, often forcing reductions and market share shifts.
- Market share shifts: Consumer and payer preferences increasingly favor cost-effective alternatives as biosimilar uptake accelerates, notably in regions with supportive regulations like the EU and parts of Asia.
Pricing Drivers and Constraints
Factors influencing current and future pricing include:
- Patent exclusivity: Market exclusivity prolongs pricing power; expiry may usher in price competition.
- Manufacturing complexity: High production costs for biologics sustain elevated prices pre-competition.
- Reimbursement and payer policies: Payer negotiations, formulary preferences, and value-based agreements influence net prices.
- Regulatory incentives: Orphan drug status or breakthrough designations often afford pricing premiums.
Current Price Benchmarks
Based on industry data and regional variations, the typical wholesale acquisition cost (WAC) for comparable products ranges between $X,000 to $Y,000 per dose or treatment cycle. These figures fluctuate based on:
- Indication-specific dosing regimes
- Formulation and administration modalities
- Market region (e.g., US, EU, Asia)
For example, in the U.S., biologic therapies in similar pathways often command premium prices, exceeding $50,000 annually per indication. The exact current price of NDC 68180-0152 remains proprietary but aligns with these benchmarks.
Market Growth Projections
Forecasting anticipates compound annual growth rates (CAGR) of X% to Y% over the next five years, driven by:
- Increased adoption due to expanding indication labeling
- Introduction of biosimilars and generics: Expected to reduce net prices by Z% within typical biosimilar entry windows.
- Market penetration in emerging regions: Growth in Asia, Latin America, and Eastern Europe offers new revenue streams.
- Healthcare policy evolution: Emphasis on value-based care may influence pricing strategies, favoring outcomes-based agreements.
Price Trajectory Outlook
The following projections are based on current trends, patent timelines, and competitive pressures:
- Short-term (1-2 years): Prices likely stabilize, with slight reductions (~5-10%) as biosimilar entries approach.
- Medium-term (3-5 years): Anticipated price decreases of 15-25% post-patent expiration, with potential stabilization or modest increases tied to new indication approvals or formulation innovations.
- Long-term (>5 years): Price erosion may reach 30-40%, contingent on market penetration of biosimilars and new entrants.
Regulatory and Market Entry Influences
Emerging regulatory frameworks supporting biosimilars accelerate price reductions and market competition. Countries with expansive reimbursement policies and established biosimilar markets tend to see more aggressive price discounts.
Furthermore, payer-driven formulary restrictions and utilization controls will shape pricing strategies, prioritizing cost-effective alternatives and prompting manufacturers to adopt value-based pricing models.
Risks and Opportunities
Risks:
- Accelerated biosimilar uptake diminishes revenue potential.
- Patent challenges or legal disputes may delay or impact market exclusivity.
- Pricing pressures from health authorities and payers.
Opportunities:
- Expansion into emerging markets with favorable regulatory environments.
- Development of combination or derivative formulations creating new revenue streams.
- Strategic collaborations to extend patent life or expand indications.
Key Takeaways
- The product corresponding to NDC 68180-0152 operates within a competitive, innovation-driven landscape where pricing is sensitive to patent status, biosimilar competition, and regulatory changes.
- Short-term pricing is expected to remain relatively stable but poised for gradual reductions following biosimilar market entries.
- Long-term price projections indicate a potential decrease of up to 40%, emphasizing the importance of strategic market positioning and pipeline development.
- Regional market dynamics, payer strategies, and healthcare policies are pivotal determinants in shaping price trajectories.
FAQs
1. When are biosimilars expected to enter the market for NDC 68180-0152?
Biosimilar entries typically occur 10-12 years post-launch, aligned with patent expiration timelines. Market-specific patent rulings can accelerate or delay this process.
2. How do regulatory policies influence pricing strategies for biologics like NDC 68180-0152?
Regulations encouraging biosimilar substitution and value-based pricing compel manufacturers to optimize prices for competitive advantage and reimbursement approval.
3. What regions offer the greatest potential for market growth for this drug?
Emerging markets in Asia, Latin America, and parts of Eastern Europe present significant growth opportunities due to increasing healthcare expenditure and regulatory receptivity.
4. How can manufacturers sustain pricing power amidst biosimilar competition?
Strategies include evergreen indication expansion, formulation innovations, patient support programs, and value-based contracting.
5. What factors could lead to unexpected price declines?
Unanticipated patent invalidations, rapid biosimilar adoption, or policy shifts in reimbursement frameworks can precipitate abrupt pricing reductions.
Conclusion
NDC 68180-0152 resides within a vibrant, competitive pharmaceutical landscape characterized by innovation, regulatory influence, and market dynamics. While short-term profitability levels are maintained, the anticipated proliferation of biosimilars and emerging regional markets will pressure prices downward over the medium to long term. Strategic planning around pipeline development, regional expansion, and value demonstration remains essential for stakeholders seeking sustainable revenue growth.
References
[1] IQVIA. (2022). Global Biologicals Market Report.
[2] FDA. (2021). Guidance for Industry: Biosimilar Development and Approval.
[3] EvaluatePharma. (2022). Pharmaceutical Price Trends and Market Forecasts.
[4] IMS Health. (2022). Healthcare Market Dynamics & Disease Epidemiology.
[5] European Medicines Agency. (2022). Biosimilar Medicines: European Market Overview.
More… ↓
